Skip to Main Content

INFORMATION FOR

Study to Evaluate Efficacy, Safety, and Tolerability of MT-7117 in Subjects With Diffuse Cutaneous Systemic Sclerosis

Conditions

Diseases of the Musculoskeletal System

Phase II

What is the purpose of this trial?

To evaluate the efficacy of MT-7117 treatment in subjects with diffuse cutaneous systemic sclerosis (dcSSc) using the American College of Rheumatology Composite Response Index in Diffuse Systemic Sclerosis (ACR CRISS) at Week 52.

  • Trial with
    Mitsubishi Tanabe Pharma Development America, Inc.
  • Start Date
    12/15/2021
  • End Date
    01/31/2023

I'm interested in volunteering

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 877.978.8343

  • Last Updated
    11/11/2022
  • Study HIC
    #2000028282